Posted by Michael Wonder on 16 Nov 2016
European Commission approves Stelara (ustekinumab) for treatment of adults with moderately to severely active Crohn’s disease
11 November 2016 - First interleukin 12/23 inhibitor licensed for Crohn’s disease.
Janssen-Cilag International announced today that the European Commission has approved the use of Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alfa antagonist or have medical contra-indications to such therapies.
Stelara is the first biologic therapy for Crohn's disease that targets interleukin 12 and 23 cytokines, known to play a key role in inflammatory and immune responses.
